European Pharmaceutical Review

FEBRUARY 27, 2024

Amgen drug development highlights – November 2023 In November 2023, Phase II trial results for immunotherapy tarlatamab demonstrated an ability to provide sustained anti-tumour activity in 40 percent of the small cell lung cancer trial patients.

Biosimilars 105

Biosimilars Pharmaceutical Companies Pharmaceutical Companies Drug Development 105

Pharmaceutical Technology

JUNE 19, 2025

GlobalData Healthcare June 19, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The oligonucleotide market is well-positioned to drive the next wave of personalised treatment. billion from 2021 to 2025 year-to-date. Credit: Kateryna Kon via Shutterstock. ASOs accounted for more than half ($3.54

Communication 52

Communication Hospitals Pharmaceutical Manufacturing Packaging 52

pharmaphorum

JUNE 17, 2025

billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.

Diabetes 59

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 59

pharmaphorum

JUNE 10, 2025

Skip to main content Tuesday 10 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 85

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 85

Pharmaceutical Technology

JUNE 6, 2025

Robert Barrie June 6, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook US health secretary Robert F Kennedy Jr. wants to ensure the ensuing the US does not lag behind other countries in drug development. Tasos Katopodis / Stringer via Getty Images. Login Registration is disabled.

Insurance Coverage and Processing 81

Insurance Coverage and Processing Communication Hospitals Drug Development 81

Viseven

JUNE 18, 2025

Previously, many organizations, including healthcare companies and facilities, were merely testing the waters. But by 2025, many have moved beyond experimentation and are actively integrating various tools and software into their workflows.”

Labelling 52

Labelling Communication Drug Development Documentation 52

Pharmaceutical Technology

MAY 23, 2023

The recent legislative reform proposals put forward by the European Commission (EC) have sparked significant discontent among pharmaceutical companies. The proposed changes aim to reduce the time between new drug launches in the 27 EU markets and the entry of generic competitors into the market.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Biosimilars Packaging 52

Viseven

JANUARY 4, 2023

This article will cover the most important areas of AI influence on the pharma industry and new drugs development. What is Artificial Intelligence in Pharmaceutical Industry? Drug Development and Discovery. The post The Use of Artificial Intelligence in the Pharmaceutical Industry appeared first on Viseven.

Drug Development 52

Drug Development Medical Records Communication Pharmaceutical Companies 52

pharmaphorum

APRIL 19, 2022

“In a situation where most of the development of treatments in Korea is mostly centred on cancer and metabolic diseases, I noticed that there weren’t any companies that were focusing on sensory diseases.”. Kim says the Dry Eye Disease market is large and growing, with analysts predicting it will hit $6 billion USD by 2025.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication Drug Development 52

Express Pharma

JANUARY 26, 2025

The Pharmaceutical Export Promotion Council of India (PHARMEXCIL) announces its renewed commitment to strengthening the strategic partnership between India and the United Arab Emirates (UAE) in the pharmaceutical sector.

Pharmaceutical Manufacturing 83

Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies Drug Development 83

Pharma Marketing Network

MAY 11, 2025

Drug Price Cuts and Policy Impact The Biden administrations Inflation Reduction Act (IRA), passed in 2022 and implemented in phases since, empowers Medicare to negotiate the prices of selected high-cost prescription drugs. market still viable for Asian pharmaceutical companies? exports or licensing agreements with U.S.

Drug Pricing 59

Drug Pricing Biosimilars Communication Immunization 59

pharmaphorum

JULY 1, 2021

Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, says Debiopharm’s Tanja Dowe. My SynBioBeta panel discussion was about the shape of biopharma in 2025 – a seemingly futuristic time that’s now less than four years away.

Drug Development 88

Drug Development Pharmaceutical Companies Pharmaceutical Companies Vaccines 88

pharmaphorum

OCTOBER 12, 2022

“We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says. By 2025, pharma’s investment in AI is expected to reach $3 billion. Forging an AI-enabled path toward precision medicine.

Drug Development 105

Drug Development Immunization Immunity Vaccines 105

Viseven

MAY 9, 2025

Source: [link] Demonstrating value Pharmaceutical companies are expected to go beyond simply proving that their treatments work they need to show that their products provide real, measurable benefits for both patients and healthcare systems. How Does the HEOR Model Work for Pharmaceutical Companies?

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 52

Express Pharma

JULY 10, 2024

With advancements in biotechnology, robust scientific capabilities, cost-effective manufacturing processes, a large workforce and a shift towards more complex biologic drugs, India is at the cusp of a huge opportunity to emerge as a leader in biopharma. On a monthly basis, this market adds around $1.16 billion.”

Vaccines 96

Vaccines Drug Development Process Improvement Biosimilars 96

Pharmaceutical Technology

MARCH 22, 2023

Several drug development trends are driving injectables demand. This includes the rising number of biologic drugs on the market, which are mostly administered parenterally. From 2025, it will be substituted with a new chapter on functional tests for the complete system.”

Packaging 52

Packaging Compounding Pharmaceutical Companies Pharmaceutical Companies 52

STAT

DECEMBER 2, 2024

But over the last couple of years, there’s been a surge of interest in a new type of treatment , one that is testing drug developers and health care practitioners alike.  Four have been snapped up by pharmaceutical giants in deals worth $1 billion or more.   Continue to STAT+ to read the full story…

Compounding 334

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Development 334

European Pharmaceutical Review

JANUARY 23, 2025

M&A dealmaking in 2025 is expected to witness continued growth, however companies need a robust partnering approach to secure future expansion. 2 It will support development of treatments for key conditions such as schizophrenia, bipolar depression, anxiety and Alzheimers disease-related psychosis and agitation.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies Drug Development 59

Express Pharma

MAY 9, 2025

Indias contract research, development and manufacturing organisation (CRDMO) sector, which serves global pharmaceutical companies, could see its revenue grow 13-15 per cent this fiscal after an estimated ~11 per cent growth in fiscal 2025 as supply chains worldwide diversify amid geopolitical uncertainties.

Pharmaceutical Companies 66

Pharmaceutical Companies Pharmaceutical Companies Drug Development 66

Pharma Leaders

JUNE 17, 2025

The pharmaceutical industry is facing unprecedented financial scrutiny, particularly with policies like the Trump Administration’s “Most Favored Nation” (MFN) pricing, which aims to lower drug costs in the US by aligning them with the lowest global prices. Source: Applied Clinical Trails , June 5 2025

Drug Development 52

Drug Development Pharmaceutical Companies Pharmaceutical Companies 52

STAT

OCTOBER 16, 2024

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You The future of health care starts on Jan.

Pharmaceutical Companies 273

Pharmaceutical Companies Pharmaceutical Companies Drug Development 273

European Pharmaceutical Review

FEBRUARY 20, 2025

For branded pharmaceutical companies, the impact may be less immediate due to their larger profit margins. As the pharmaceutical industry navigates these challenges, strategic adaptation and international cooperation will be key to maintaining supply chain resilience and ensuring continued innovation in drug development.

Generic Medicine 20

Generic Medicine Drug Pricing Pharmaceutical Manufacturing Hospitals 20

BioPharma Dive

JUNE 11, 2025

Published June 11, 2025 Ben Fidler Senior Editor post share post print email license The FDA on June 11, 2025 approved Nuvation's Ibtrozi for ROS1-positive non-small cell lung cancer. Sanofi’s $9.1 Track the deals that are happening here. Sanofi’s $9.1

Drug Pricing 106

Drug Pricing Immunization Immunity Drug Development 106